Drug updated on 12/11/2024
| Dosage Form | Gel (topical; 8.8%) |
| Drug Class | Proteolytic enzymes |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for eschar removal in adults and pediatric patients with deep partial thickness and/or full thickness thermal burns
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Nexobrid® is effective for debridement of deep burns, leading to improved functional and cosmetic outcomes, reduced scarring, and enhanced quality of life, with faster healing times and reduced hospital stays.
- High patient satisfaction is reported, supported by enhanced analgosedation and/or locoregional anesthesia protocols, with fewer cases of sepsis and blood transfusions, and prevention of compartment syndrome.
- The review does not specify population subgroups or provide comparative effectiveness data against other treatments.
- Nexobrid® is described as a safe treatment for eschar removal, with no strong evidence of adverse events like coagulopathy or burn wound infection reported in the reviewed studies.
- High patient satisfaction related to pain management protocols, involving enhanced analgosedation and/or locoregional anesthesia, further supports a favorable safety profile.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| NexoBrid (anacaulase-bcdb) Prescribing Information. | 2024 | Vericel Corporation, Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Bromelain-based enzymatic burn debridement: A systematic review of clinical studies on patient safety, efficacy and long-term outcomes | 2023 | International Wound Journal |